Objective: The dysregulation of neuro-inflammation is one of the attributes of the pathogenesis of Alzheimer’s disease (AD). Over-expression of complement proteins co-localizes with neurofibrillary tangles, thereby indicating that a complement system may be involved in neuro-inflammation. Here, we report the influence of complement activation on the neuro-inflammation using a microglial cell line.

Methods: first, we performed a cytotoxic assay using the microglial cells BV-2. Second, after treatment of BV-2 cells with Aβ42 and/or C5a, the anaphylatoxin derived from C5, we determined the expression levels of the pro-inflammatory factors TNF-α, IL-1β, and IL-6. Finally, we explored whether this neuro-inflammatory response was mediated by JAK/STAT3 signaling.

Results: C5a had an enhanced effect on the neural cell viability of BV-2 cells treated with Aβ42. In addition, C5a also increased the Aβ-induced neuro-inflammatory response, and these effects were blocked by the C5aR antagonist, PMX205. Finally, we demonstrated that the neuro-inflammatory responses induced by Aβ and C5a were mediated through JAK/STAT3 signaling. By blocking this pathway with an antagonist, AG490, the expression of TNF-α, IL-1β, and IL-6 was alleviated.

Conclusion: The complement protein C5a could exaggerate the Aβ-induced neuro-inflammatory response in microglia, and C5aR may be a potential therapeutic tool for AD treatment.

Key words: Alzheimer’s disease; β-amyloid; complement system; neuro-inflammatory response; STAT3.

Introduction

Alzheimer’s disease (AD) is one of the neurodegenerative diseases that frequently occur in elderly populations; it is characterized by cognition impairment and progressive memory loss [1]. An estimated 60 million people suffer from AD, and approximately 10 million new cases are diagnosed each year worldwide [2]. Currently, accumulation of fibrillar amyloid β (fAβ) surrounding the microglial cells and inducing the inflammatory response is believed to be a pathogenesis of AD [3]; microglial cells surrounding the senile plaques are further recruited, and neurotoxic factors (such as IL-1, TNF-α, and IL-6) are released. It aggravates the inflammatory responses, although microglial cells normally function as macrophages to help eliminate Aβ [4]. Treatment with Aβ oligomer in primary microglial cells can increase the expressions of IL-1β and TNF-α, which are significantly increased in serum and cerebrospinal fluid of AD patients [5,6]. Afterward, these inflammatory factors would feed back to the neurons and microglial cells, thereby promoting the production of other inflammatory factors. Hence, a vicious cycle is developed between the microglial cells that are activated by accumulation of Aβ and the inflammatory mediators released by microglial cells, thereby resulting in the denaturation and necrosis of neurons [7,8].

Complement system plays an important role in the identification and removal of invasive pathogenic microorganisms as one part of self-defense immune system [9,10]. Misfolded and aggregated proteins or reactive microglia found in neurodegenerative diseases can activate the complement pathways [11,12]. C5a and its receptor (C5aR)
are prominently up-regulated in microglia co-localized with amyloid plaques in AD mouse models [13]. Brain tissues of AD patients revealed an increased expression of two C5 receptors, CD88, and C5L2, which was associated with abundant neurofibrillary tangles when compared with age-matched counterparts [14]. Continuously activated complement system results in excessive production of C5a and subsequently exaggerates the neuro-inflammatory response [15]. In addition, C5a enhances the injury of fibrillary amyloid β to the primary neurons [16]. Hence, blocking the C5a/C5aR signaling activation axis alleviates the neuro-inflammatory alterations to AD pathologies. Both C5a–targeting vaccines and C5a receptor antagonist, PMX205, have shown improved contextual memory and reduced cerebral amyloid plaque [17, 18]. However, the underlying mechanisms by which C5a/C5aR are involved in AD pathogenesis have not been yet elucidated.

Janus kinase–signal transducer and activator of transcription (JAK–STAT) has become one of the important regulatory pathways associated with AD pathogenesis [19]. STAT3, a critical nuclear transcription factor in this pathway, is involved in the neuro-inflammatory response to AD pathogenesis [19]. STAT3, a critical nuclear transcription factor associated with AD pathogenesis is involved in the neuro-inflammatory response caused by the activation of microglial cells at the onset of AD, thereby producing multiple inflammatory factors [20]. C5a was previously reported to induce STAT3 activation [21]. However, the influence of this effect in the context of AD has not been studied. Therefore, we used an Aβ oligomer to induce the in vitro inflammatory response of microglial cells and investigated the role of C5a/C5aR pathway in this process [22]. We also tried to explore the effects of C5a-induced STAT3 activation on Aβ oligomer-induced neuro-inflammatory response.

Materials and methods

Reagents
Cell culture medium high-glucose Dulbecco’s modified eagle medium (DMEM) and fetal bovine serum (FBS) were from Gibco, USA; 0.25% trypsin and penicillin-streptomycin were from Hyclone, USA; CCK-8 kit was from Dojindo, Japan; Aβ1-42 peptides, hexafluorisopropanol (HFIP) and DMSO were from Sigma, USA; 1-42 peptides, hexafluoroisopropanol (HFIP) and DMSO were from Sigma, USA; BCA protein assay kit was from Thermo, USA; rabbit anti-p–STAT3 and STAT3 polyclonal antibodies were from Cell Signaling Technology, USA; PVDF membrane and ECL kit were from Millipore, Germany.

Cell culturing
Microglial BV-2 cells were from the Shanghai Cell Bank of Chinese Academy of Sciences. BV-2 cells were cultured in a medium containing DMEM supplemented with 10% FBS in the 37 °C, 5% CO2 humid atmosphere incubator.

CCK-8 proliferation assay
Microglial cells were inoculated onto a 96-well plate (105/well). After 12 h, Aβ1-42 oligomers at different concentrations were added, and BV cells were cultured for another 24 h. The supernatant was replaced with a fresh culture medium, after which 10 μL CCK-8 reagent were added to each well and incubated for 2 h. Subsequently, OD450 values were determined using a microplate reader.

Western blot
After cell lysis and centrifugation of the cell extracts at 4 °C for 15 min at 12,000 rpm, the supernatant that contains the cellular proteins was collected and used in Western blot experiments. 20 μg of total proteins were loaded and separated through sodium dodecyl sulfonate polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto a PVDF membrane. After incubation in blocking solution for 2 h, the PVDF membrane was probed with primary antibodies to p–STAT3 (1:1,000), STAT3 (1:500), and β-actin (1:1,000) at 4 °C overnight. After washing with TBST and probing with the relevant secondary antibodies, an ECL kit was used to reveal specific protein expression.

qRT-PCR
Total RNA was extracted using Trizol according to the manufacturer’s instructions. Then, 500 ng total RNA were reverse transcribed into cDNA. PCR conditions: 37 °C for 15 min, 85 °C for 5 s, and termination at 4 °C in a 10 μL system. The product of cDNA was added into the RT–PCR reaction system as template for the following procedures: initial denaturation for 30 s at 95 °C; PCR reaction for 5 s at 95 °C and 30 s at 60 °C followed by 40 cycles; and termination at 95 °C for 15 s, 60 °C for 1 min, and 95 °C for 15 s in 20 μL system. The pairs of primer sequences were: STAT-3: (Sense) 5’-TCGTGG

Figure 1. Cell viability was measured by a CCK8 assay after treatment with Aβ1-42, C5a, and PMX205 in BV-2 for 24 h.
Results

C5a enhances the cytotoxic effect of $\text{AB}_{42}$ on BV-2 cells

$\text{AB}_{42}$ and C5a inhibited the cell viability of microglia. Thus, we tried to examine the effects of co-treatment with $\text{AB}_{42}$ and C5a on microglia. After a 24 h treatment, the cell viability of BV-2 was tested with a CCK8 assay. As shown in Figure 1, the cell number was reduced by about 50% in the $\text{AB}_{42}$ and C5a co-treatment group compared with $\text{AB}_{42}$ alone group. Cell growth was restored after adding PMX205.

C5a raises the neuro-inflammatory response to $\text{AB}_{42}$

To explore the role of C5a on the inflammatory response in BV-2 cells after exposure to $\text{AB}_{42}$, BV-2 cells were incubated with $\text{AB}_{42}$, C5a, $\text{AB}_{42}$ plus C5a, or PMX205 for 24 h. The production of inflammatory factors, TNF-$\alpha$, IL-1$\beta$, and IL-6, were analyzed. As shown in Figure 2A, the expression of these pro-inflammatory molecules increased in both $\text{AB}_{42}$ and C5a groups and was further up-regulated in $\text{AB}_{42}$ plus C5a group, whereas their expression was substantially reversed in $\text{AB}_{42}$ plus PMX205 group. We further measured the secreted TNF-$\alpha$ and IL-6 with ELISA kits. Similarly, more TNF-$\alpha$ and IL-6 were produced in the $\text{AB}_{42}$ plus C5a group than in the $\text{AB}_{42}$ or C5a alone group and were decreased in the $\text{AB}_{42}$ plus PMX205 group (Figure 2B).

C5a enhances the $\text{AB}_{42}$-induced activation of STAT3 in BV-2 cells

Next, we examined whether STAT3 was involved in the stimulation process of $\text{AB}_{42}$ and C5a in BV-2 cells. Figure 3 shows the increase in the phosphorylation of STAT3 after treatment with either $\text{AB}_{42}$ or C5a. This increase was further reinforced in the $\text{AB}_{42}$ and C5a combination group. As expected, blocking C5a with PMX205 reduced the activation of STAT3.
C5aR1, one of two receptors of C5a, is expressed on the surface of primary microglia isolated from wild-type mice when compared with C5aR1 knockout mice. A previous experiment demonstrated that C5aR1+ cells surrounded Aβ plaques in AD mouse models [13], thereby suggesting that C5a/C5aR plays a role in the pathogenesis of AD. Other studies have reported that the levels of complement components increase in an age-dependent manner, thereby subsequently being able to activate more strongly complement pathways in neurons and microglia [22]. This dysregulation of complement cascade enhances the neuro-inflammatory response to fibrillary Aβ plaques in AD [23]. Hence, approaches to block C5a/C5aR activation are hypothesized to help preventing neural damage and cognitive decline. In our study, we confirmed that utilization of C5aR1 antagonist, PMX205, restored cell viability to some extent. Moreover, blocking the C5a/C5aR interaction had no influence on other complement proteins, such as C1q, C3, and C4 [13, 24], thereby suggesting that the benefit of part of the complement system is preserved.

Chronic inflammatory response induced by persistently activated microglia is considered one of the major pathogenesis of AD. C5a, a pro-inflammatory factor, is actively produced after complement activation induced by Aβ deposits, which is one of the major mechanisms for microglia activation [14, 25]. The activation of microglia and the activation of the complement system further induces neuro-inflammation [23, 26]. Constant production of pro-inflammatory and complement components enhances the release of amyloid peptides [27, 28]. This self-sustaining neuro-inflammation loop between the activated microglia, complement system, and Aβ plaques ultimately results in the loss of synapses and the decline of cognitive function in AD patients [29, 30]. In the present study, we demonstrated that targeting C5a and prohibiting its receptor C5aR obviously suppressed the production of pro-inflammatory factors induced by Aβ oligomers; this finding was consistent with a previous suggestion that C5aR could be a promising therapeutic target for AD.

We further demonstrated that the down-regulation of pro-inflammatory factors via treatment with C5aR antagonist was mediated through JAK/STAT3 signaling. STAT3, an important nuclear transcription factor of STAT family, mediates the signal transduction of multiple cytokines into the nucleus, thereby subsequently affecting the transcription of target genes and regulating cell function. Increasing evidence supports that the dysregulation of STAT3 is associated with the chronic inflammatory injuries in AD [31]. STAT3 is highly acti-
vated in brain tissue in AD mouse model [32]. In addition, STAT3 is involved in regulating the transcription of multiple inflammatory factors [19]. Significant decrease in the expression levels of inflammatory factors released by activated microglial cells, such as TNF-α and NO, was observed after the activation of STAT3 was blocked by AG490, a selective inhibitor of JAK signal pathway [33]. Moreover, STAT3 is involved in chronic activation of microglial cells and release of inflammatory factors induced by Aβ oligomers [34,35].

In conclusion, targeting a molecule of the complement system is an effective alternative for AD treatment. Moreover, these results may further improve our understanding of AD pathogenesis, in which chronic neuro-inflammatory response driven by both microglia and complement activation may play a pivotal role.

CONFLICT OF INTERESTS

Dr. Huang was financially supported by an educational grant from Zhongshan Hospital, Fudan University and Dr. An was financially supported by an grant from Yangpu District Mental Health Center of Shanghai. The authors have no potential conflict of interests.

REFERENCES

3. Baranello RJ, Bharani KL, Padmaraju V, Chopra N, Lahiri DK, Greig NH, Fudan University and Dr. An was financially supported by an grant from Yangpu District Mental Health Center of Shanghai. The authors have no potential conflict of interests.